Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics

Ruijie Xie; Teresa Seum; Sha Sha; Kira Trares; Bernd Holleczek; Hermann Brenner; Ben Schöttker

doi:10.1186/s12933-025-02581-3

Abstract

1 min read

Incorporating seven metabolomic biomarkers in the SCORE2-Diabetes model enhanced its ability to predict MACE in patients with type 2 diabetes. Given the latest cost reduction and standardization efforts, NMR metabolomics has the potential for translation into the clinical routine.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Preprint2024

Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics

Ruijie Xie, Teresa Seum, Sha Sha, Kira Trares, Bernd Holleczek, Hermann Brenner, Ben Schöttker

Preprint2024

Metabolomics data improve 10-year cardiovascular risk prediction with the SCORE2 algorithm for the general population without cardiovascular disease or diabetes

Ruijie Xie, Sha Sha, Lei Peng, Bernd Holleczek, Hermann Brenner, Ben Schöttker

Article2025

Metabolomics data improve 10-year cardiovascular risk prediction with the SCORE2 algorithm for the general population without cardiovascular disease or diabetes

Ruijie Xie, Sha Sha, Lei Peng, Bernd Holleczek, Hermann Brenner, Ben Schöttker

Preprint2024

Sex-specific proteomic signatures improve cardiovascular risk prediction for the general population without cardiovascular disease or diabetes

Ruijie Xie, Tomislav Vlaški, Sha Sha, Hermann Brenner, Ben Schoettker

Preprint2022

Protein Biomarkers and Cardiovascular Outcomes in People with Type 2 Diabetes and Acute Coronary Syndrome: The ELIXA Biomarker Study

Hertzel C. Gerstein, Sibylle Hess, Brian Claggett, Kenneth Dickstein, Lars Køber, Aldo Maggioni, John J.V. McMurray, Jeffrey L. Probstfield, Matthew C. Riddle, Jean‐Claude Tardif, Marc A. Pfeffer